Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
This study is looking to see whether the combination of Tucidinostat and nab-paclitaxel is safe and effective in participants with advanced HR+/HER2- breast cancer.
HR+/HER2- Breast Cancer
DRUG: Tucidinostat|DRUG: nab-paclitaxel
Objective Response Rate（ORR）, ORR by RECIST 1.1,the total proportion of patients with complete response（CR）, partial response（PR）, 2 years
Progression-free survival(PFS), Time from treatment until disease progression or death, 2 years|Disease Control Rate （DCR）, the total proportion of patients with complete response（CR）, partial response（PR）and Stable Disease（SD）, 2 years|Disease Control Rate （DCR）, Time from treatment until death from any cause, 2 years
This study is looking to see whether the combination of Tucidinostat and nab-paclitaxel is safe and effective in participants with advanced HR+/HER2- breast cancer.